Table 1 Baseline characteristics. The median duration of acalabrutinib use was 41.2Â months
From: Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Variable | Total (n = 280) | No baseline HTN (n = 115) | Baseline HTN (n = 165) |
|---|---|---|---|
Age at acalabrutinib initiation, mean (SD) | 63.7 (10.1) | 61.5 (10.9) | 65.2 (9.3) |
Sex, n (%) | Â | Â | Â |
Male | 199 (71.1) | 79 (68.7) | 120 (72.7) |
Female | 81 (28.9) | 36 (31.3) | 45 (27.3) |
Race, n (%) | Â | Â | Â |
White | 270 (96.8) | 111 (96.5) | 159 (97.0) |
Black | 5 (1.8) | 3 (2.6) | 2 (1.2) |
Other* | 5 (1.8) | 1 (0.9) | 4 (2.4) |
BMI, mean (SD) | 28.1 (5.5) | 26.2 (4.5) | 29.5 (5.8) |
BMI, n (%) | Â | Â | Â |
 < 25 | 78 (27.9) | 43 (37.4) | 35 (21.2) |
25–29.9 | 116 (41.4) | 53 (46.1) | 63 (38.2) |
 ≥ 30 | 86 (30.7) | 19 (16.5) | 67 (40.6) |
Other baseline traditional HTN risk factors | Â | Â | Â |
DM | 24 (8.6) | 9 (7.8) | 15 (9.1) |
MI | 12 (4.3) | 4 (3.5) | 8 (4.8) |
CKD | 7 (2.5) | 3 (2.6) | 4 (2.4) |
CHF | 12 (4.3) | 4 (3.5) | 8 (4.8) |
AF/Aflutter | 40 (14.3) | 16 (13.9) | 24 (14.5) |
CVA/TIA | 7 (2.5) | 3 (2.6) | 4 (2.4) |
Smoking status | Â | Â | Â |
Never | 166 (59.3) | 79 (68.7) | 87 (52.7) |
Previous | 93 (33.2) | 27 (23.5) | 66 (40.0) |
Current | 21 (7.5) | 9 (7.8) | 12 (7.3) |
Primary malignancy, n (%) | Â | Â | Â |
CLL | 249 (88.9) | 104 (90.4) | 145 (87.9) |
MCL | 6 (2.1) | 2 (1.7) | 4 (2.4) |
Other†| 25 (8.9) | 9 (7.8) | 16 (9.7) |
RAI stage, n (%)** | Â | Â | Â |
0 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
1 | 43 (15.4) | 20 (17.4) | 23 (13.9) |
2 | 46 (16.4) | 18 (15.7) | 28 (17.0) |
3 | 27 (9.6) | 15 (13.0) | 12 (7.3) |
4 | 90 (32.1) | 38 (33.0) | 52 (31.5) |
Unknown | 74 (26.4) | 24 (20.9) | 50 (30.3) |
Baseline ECOG performance status, n (%) | Â | Â | Â |
0 | 107 (38.2) | 43 (37.4) | 64 (38.8) |
1 | 164 (58.6) | 68 (59.1) | 96 (58.2) |
2 | 8 (2.9) | 3 (2.6) | 5 (3.0) |
3 | 1 (0.4) | 1 (0.9) | 0 (0.0) |
4 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Treatment history, n (%) | Â | Â | Â |
Number of prior anticancer therapies, median (IQR) | 2 (2) | 2 (3) | 2 (2) |
Concomitant chemotherapy | 99 (35.4) | 42 (36.5) | 57 (34.5) |
Prior chemotherapy | 137 (48.9) | 53 (46.1) | 84 (50.9) |
Prior monoclonal antibody | 171 (61.1) | 72 (62.6) | 99 (60.0) |
Prior ibrutinib therapy | 72 (25.7) | 26 (22.6) | 46 (27.9) |
Prior targeted therapy (not Ibrutinib) | 26 (9.3) | 12 (10.4) | 14 (8.5) |
Prior immunomodulatory | 31 (11.1) | 16 (13.9) | 15 (9.1) |
CY3PA4 inhibitor | 27 (9.6) | 8 (7.0) | 19 (11.5) |
Cyclosporine during ibrutinib use | 4 (1.4) | 1 (0.9) | 3 (1.8) |
No prior anticancer therapies, n (%) | 77 (27.5) | 33 (28.7) | 44 (26.7) |
Baseline SBP, mmHg | Â | Â | Â |
 < 100 | 6 (2.1) | 6 (5.2) | 0 (0.0) |
100–119 | 75 (26.8) | 73 (63.5) | 2 (1.2) |
120–129 | 68 (24.3) | 36 (31.3) | 32 (19.4) |
130–139 | 50 (17.9) | 0 (0.0) | 50 (30.3) |
140–179 | 78 (27.9) | 0 (0.0) | 78 (47.3) |
180 +  | 3 (1.1) | 0 (0.0) | 3 (1.8) |
Baseline DBP, mmHg | Â | Â | Â |
 < 70 | 124 (44.3) | 78 (67.8) | 46 (27.9) |
70–79 | 101 (36.1) | 33 (28.7) | 68 (41.2) |
80–89 | 44 (15.7) | 4 (3.5) | 40 (24.2) |
90–119 | 11 (3.9) | 0 (0.0) | 11 (6.7) |
Baseline anti-HTN medications | Â | Â | Â |
Beta-blocker | 67 (23.9) | 25 (21.7) | 42 (25.5) |
ACE inhibitor/ARB | 80 (28.6) | 21 (18.3) | 59 (35.8) |
Calcium channel blocker | 29 (10.4) | 5 (4.3) | 24 (14.5) |
Diuretic‡ | 46 (16.4) | 11 (9.6) | 35 (21.2) |
Other§ | 10 (3.5) | 2 (1.7) | 8 (4.8) |